Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi

Amaç: Metabolik sendromun (MS) patogenezinde inflamasyon önemli rol oynamaktadır. Bu çalışmada, MS’li hastalarda fluvastatin tedavisinin inflamatuvar belirteçler üzerine etkisi araştırıldı. Ça lış ma pla nı: Çalışmaya MS tanılı 47 hasta (36 kadın, 11 erkek; ort. yaş 55±8) alındı. Metabolik sendrom tanısı NCEP ATP III ölçütlerinden en az üçünün varlığıyla kondu. Bütün hastalara altı hafta boyunca 80 mg fluvastatin tedavisi uygulandı. Tedavi öncesi ve sonrasında laboratuvar parametreleri ölçüldü; periferik kan lökositleri akım sitometri yöntemiyle değerlendirildi. Hasta grubunun verileri, yaş ve cinsiyet uyumlu 47 sağlıklı bireyden (33 kadın, 14 erkek; ort. yaş 52±8) oluşan kontrol grubuyla karşılaştırıldı. Bul gu lar: Tedavi sonrasında total kolesterol, LDL-kolesterol ve trigliserid düzeylerinde (p<0.005) ve C-reaktif protein düzeyinde (p<0.05) anlamlı düşüş görüldü. Metabolik sendromlu grupta 33 hastada (%70.2) insülin direnci vardı. İnsülin direncinde tedavi sonrasında anlamlı değişiklik olmadı. Akım sitometrik incelemede, lökosit yüzey antijenlerinden CD16+56, CD8+(CD28+), granülosit CD11c ve total lenfositte tedavi öncesine göre anlamlı azalma (p<0.05), CD4/CD8 oranında ise anlamlı artış görüldü (p<0.05). Tedavi öncesinde MS’li hastalarda, monositlerdeki CD14, CD11b, CD11c ve CD63’ün, granülositlerdeki CD11b ve CD11c’nin ortalama floresan yoğunluğu kontrol grubuna göre anlamlı derecede yüksekti (p<0.05). Statin tedavisi sonrasında lenfositlerin yüzeyindeki CD3’ün, monositlerin ve granülositlerin yüzeyindeki CD11b ve CD11c’nin ortalama floresan yoğunluğunda anlamlı azalma sağlandı (p<0.05); bu değerlerin hepsi tedavi sonrasında kontrol grubu ile benzerlik içindeydi (p>0.05). So nuç: Bulgularımız metabolik sendrom patogenezinde inflamasyonun önemli rol oynayabileceğini ve statin tedavisi ile bu etkinin kontrol altına alınabileceğini göstermektedir.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Endokrinoloji ve Metabolizma Hematoloji Geriatri ve Gerontoloji Kalp ve Kalp Damar Sistemi Pediatri

The effect of statin treatment on inflammation in patients with metabolic syndrome

Öz:

Objectives: Inflammation plays an important role in the pathogenesis of metabolic syndrome (MS). We investigated the effect of fluvastatin treatment on inflammatory markers in patients with MS. Study design: The study included 47 patients (36 females; 11 males; mean age 55±8 years) with MS. The diagnosis of MS was based on the presence of at least three criteria of the NCEP ATP III guidelines. All the patients received 80 mg fluvastatin treatment for six weeks. Laboratory parameters were measured before and after treatment, and flow cytometric analysis of peripheral blood leukocytes was performed. The results were compared with those of 47 age- and sexmatched healthy controls (33 females, 14 males; mean age 52±8 years). Results: Fluvastatin treatment resulted in significant decreases in levels of total cholesterol, LDL cholesterol, triglyceride (p<0.005), and C-reactive protein (p<0.05). Thirty-three patients (70.2%) had insulin resistance, which remained unchanged following treatment. Flow cytometric analysis after treatment showed significant decreases in total lymphocytes, and in surface antigens of CD16+56 and CD8+(CD28+) on leukocytes, CD11c on granulocytes, and a significant increase in the CD4/CD8 ratio (p<0.05).Compared to the control group, the mean baseline values of fluorescence density (FD) of CD14, CD11b, CD11c, and CD63 on monocytes, and CD11b and CD11c on granulocytes were significantly higher in patients with MS (p<0.05). Following fluvastatin treatment, there were significant decreases in the mean FD of CD3 on lymphocytes, and of CD11b and CD11c on both monocytes and granulocytes (p<0.05); of these, all FD values were similar to those in the control group (p>0.05). Conclusion: Our data demonstrate that inflammation may have a significant role in the pathogenesis of MS and that this effect can be controlled with statin treatment.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Endokrinoloji ve Metabolizma Hematoloji Geriatri ve Gerontoloji Kalp ve Kalp Damar Sistemi Pediatri

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
2. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999;22 Suppl 3:C25-30.
3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
4. Onat A, Sansoy V. Metabolic syndrome, major culprit of coronary disease among Turks: its prevalence and impact on coronary risk. [Article in Turkish] Türk Kardiyol Dern Arş 2002;30:8-15.
5. Onat A. Erişkinlerimizde kalp hastalıkları prevalansı, yeni koroner olaylar ve kalpten ölüm sıklığı. In: Onat A, editör. TEKHARF, Yüzyıl dönümünde Türk erişkin koroner risk haritası ve koroner kalp hastalığı. İstanbul: Mas Matbaacılık; 2001, s. 17-26.
6. Onat A, Ceyhan K, Sansoy V, Keleş İ, Erer B, Uysal Ö. Erişkinlerimizin yarısında bulunan dislipidemi ve metabolik sendromun özellikleri ve kombine hiperlipidemi ile ilişkisi: aynı zamanda plazma trigliserid düzeyi üst sınırı konusunda bir katkı. Türk Kardiyol Dern Arş 2001;29:274-85.
7. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001;19:523-8.
8. Damcı T. Sendrom X. İlkova H, editör. Diabet, obezite ve metabolizma hastalıkları. İstanbul: İ. Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Komisyonu; Yayın No: 20; 2000. p. 129-31.
9. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1339-42.
10. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, et al. Design & rationale of the Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997;80:287-93.
11. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
13. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
15. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999; 41:402-17.
16. Nègre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345:259-68.
17. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
18. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study. Ann Intern Med 2003;139:97-104.
19. van Nieuw Amerongen GP, Vermeer MA, Nègre- Aminou P, Lankelma J, Emeis JJ, van Hinsbergh VW. Simvastatin improves disturbed endothelial barrier function. Circulation 2000;102:2803-9.
20. Undas A, Brozek J, Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 2002;48:287-96.
21. Humphries KH, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007;154:908-13.
22. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7.
23. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.
24. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
25. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
26. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
27. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
28. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
29. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353:118-9.
30. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet 1999;353:1274.
31. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism. 2007;56:491-6.
32. Cronstein BN, Weismann G. The adhesion molecules of inflammation. Arthritis Rheum 1993;36: 147-57.
33. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60:577-84.
34. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez JJ, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006;98:70-4.
35. Jy W, Minagar A, Jimenez JJ, Sheremata WA, Mauro LM, Horstman LL, et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMPmonocyte conjugates in multiple sclerosis. Front Biosci 2004;9:3137-44.
36. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007;153:881-8.
37. Serrano CV Jr, Yoshida VM, Venturinelli ML, D’Amico E, Monteiro HP, Ramires JA, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 2001; 157:505-12.
38. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-7.

APA	Aydin M, ONUK T, DOĞAN S, YILDIRIM N, Demirci E, Kalaycıoğlu E, MADAK H, AKTOP Z, ÇETİNER M, SAYIN M, KARAASLAN S (2009). Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. , 26 - 34.
Chicago	Aydin Mustafa,ONUK Tolga,DOĞAN Sait Mesut,YILDIRIM Nesligül,Demirci Erkan,Kalaycıoğlu Ezgi,MADAK Hediye,AKTOP Ziyaeddin,ÇETİNER Mehmet Ali,SAYIN Muhammet Raşit,KARAASLAN Sibel Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. (2009): 26 - 34.
MLA	Aydin Mustafa,ONUK Tolga,DOĞAN Sait Mesut,YILDIRIM Nesligül,Demirci Erkan,Kalaycıoğlu Ezgi,MADAK Hediye,AKTOP Ziyaeddin,ÇETİNER Mehmet Ali,SAYIN Muhammet Raşit,KARAASLAN Sibel Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. , 2009, ss.26 - 34.
AMA	Aydin M,ONUK T,DOĞAN S,YILDIRIM N,Demirci E,Kalaycıoğlu E,MADAK H,AKTOP Z,ÇETİNER M,SAYIN M,KARAASLAN S Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. . 2009; 26 - 34.
Vancouver	Aydin M,ONUK T,DOĞAN S,YILDIRIM N,Demirci E,Kalaycıoğlu E,MADAK H,AKTOP Z,ÇETİNER M,SAYIN M,KARAASLAN S Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. . 2009; 26 - 34.
IEEE	Aydin M,ONUK T,DOĞAN S,YILDIRIM N,Demirci E,Kalaycıoğlu E,MADAK H,AKTOP Z,ÇETİNER M,SAYIN M,KARAASLAN S "Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi." , ss.26 - 34, 2009.
ISNAD	Aydin, Mustafa vd. "Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi". (2009), 26-34.

APA	Aydin M, ONUK T, DOĞAN S, YILDIRIM N, Demirci E, Kalaycıoğlu E, MADAK H, AKTOP Z, ÇETİNER M, SAYIN M, KARAASLAN S (2009). Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. Türk Kardiyoloji Derneği Arşivi, 37(1), 26 - 34.
Chicago	Aydin Mustafa,ONUK Tolga,DOĞAN Sait Mesut,YILDIRIM Nesligül,Demirci Erkan,Kalaycıoğlu Ezgi,MADAK Hediye,AKTOP Ziyaeddin,ÇETİNER Mehmet Ali,SAYIN Muhammet Raşit,KARAASLAN Sibel Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. Türk Kardiyoloji Derneği Arşivi 37, no.1 (2009): 26 - 34.
MLA	Aydin Mustafa,ONUK Tolga,DOĞAN Sait Mesut,YILDIRIM Nesligül,Demirci Erkan,Kalaycıoğlu Ezgi,MADAK Hediye,AKTOP Ziyaeddin,ÇETİNER Mehmet Ali,SAYIN Muhammet Raşit,KARAASLAN Sibel Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. Türk Kardiyoloji Derneği Arşivi, vol.37, no.1, 2009, ss.26 - 34.
AMA	Aydin M,ONUK T,DOĞAN S,YILDIRIM N,Demirci E,Kalaycıoğlu E,MADAK H,AKTOP Z,ÇETİNER M,SAYIN M,KARAASLAN S Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. Türk Kardiyoloji Derneği Arşivi. 2009; 37(1): 26 - 34.
Vancouver	Aydin M,ONUK T,DOĞAN S,YILDIRIM N,Demirci E,Kalaycıoğlu E,MADAK H,AKTOP Z,ÇETİNER M,SAYIN M,KARAASLAN S Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi. Türk Kardiyoloji Derneği Arşivi. 2009; 37(1): 26 - 34.
IEEE	Aydin M,ONUK T,DOĞAN S,YILDIRIM N,Demirci E,Kalaycıoğlu E,MADAK H,AKTOP Z,ÇETİNER M,SAYIN M,KARAASLAN S "Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi." Türk Kardiyoloji Derneği Arşivi, 37, ss.26 - 34, 2009.
ISNAD	Aydin, Mustafa vd. "Metabolik sendromlu hastalarda statin tedavisinin inflamasyon üzerine etkisi". Türk Kardiyoloji Derneği Arşivi 37/1 (2009), 26-34.